Text Size

The Role of Dendritic Cells in Hepatitis C Infection

This study has been completed.
Sponsor:
Collaborator:
Schering-Plough
Information provided by:
University College, London
ClinicalTrials.gov Identifier:
NCT00723242
First received: July 24, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted
  Purpose

The role of the dendritic cells, the most potent antigen presenting cells, in the establishment of chronic hepatitis C is not established. The study aims to define whether the dendritic cells are affected by the hepatitis C virus and whether that bears an impact on the antiviral immune response they generate. The hypothesis is explored by investigating a group of patients prior to and after the initiation of standard treatment for hepatitis C with pegylated Interferon and Ribavirin.


Condition Intervention
Chronic Hepatitis C Infection
 Drug: Viraferon-peg and Rebetol

Study Type: Interventional
Study Design: Primary Purpose: Basic Science

Resource links provided by NLM:

Drug Information available for: Ribavirin
U.S. FDA Resources

Further study details as provided by University College, London:

Primary Outcome Measures:
  • Basic science research (immunology of hepatitis C)in hepatitis c patients receiving established, standard antiviral treatment (pegylated Interferon+Ribavirin) [ Designated as safety issue: No ]

Study Start Date: April 2002
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • anti-HCV positive
  • HCV RNA positive

Exclusion Criteria:

  • contraindications for antiviral treatment
  • concurrent chronic viral infections
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00723242

Locations
United Kingdom
University College Hospital
London, United Kingdom, NW1 2BU
Sponsors and Collaborators
University College, London
Schering-Plough
  More Information

No publications provided

Responsible Party: Professor Nikolai V. Naoumov
ClinicalTrials.gov Identifier: NCT00723242     History of Changes
Other Study ID Numbers: unknown
Study First Received: July 24, 2008
Last Updated: July 24, 2008
Health Authority: United Kingdom: National Health Service

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
 Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Ribavirin
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antimetabolites
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 21, 2013